<DOC>
	<DOC>NCT00252707</DOC>
	<brief_summary>In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety of gefitinib with docetaxel.</brief_summary>
	<brief_title>Iressa 2nd Line Phase III Study in Japan</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>You are "histologically" or "cytologically" confirmed to have recurrent or metastatic NSCLC You have been treated with chemotherapy including platinums for NSCLC. You have received treatment for nonsmall lung cancer within 4 weeks before your participation in this study (except for specific therapies) You have or had any disease of acute lung injury, idiopathic pulmonary fibrosis, pulmonary pneumonia, or pneumoconiosis evident on the Xray You have or had any disease of radiation pneumonia or druginduced pneumonia, which requires treatment with corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>